Alxn1840
Wilson Disease
Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Alexion Pharmaceuticals, Inc.
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05047523CT.gov Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease | — | Terminated | — | — | — |
NCT04526210CT.gov Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants | — | Completed | — | — | — |
NCT04573309CT.gov Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 | — | Completed | — | — | — |
NCT04526197CT.gov Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. | — | Completed | — | — | — |
NCT05641311CT.gov Pharmacokinetic Study of Oral ALXN1840 in Japanese and Non-Japanese Adult Healthy Participants | — | Completed | — | — | — |
NCT03403205CT.gov Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease | — | Terminated | — | — | — |
NCT02273596CT.gov Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients | — | Completed | — | — | — |
NCT05686564CT.gov Early Access Program for ALXN1840 in Patients With Wilson Disease | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Wilson Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Alxn1840 (this asset) | Alexion Pharmaceuticals, Inc. | P3 | BB · 66 |
| Zinc Acetate | Nobelpharma | P4 | BBB |
| Teta 4Hcl | Orphalan | P3 | BBB |
| Zinc D-Gluconate (1:2) | Jun Li | P4 | BBB |
| Trientine | Excelsior | P3 | BB |
| Penicillamine | Orphalan | P3 | BB |
| Gandouling | Jun Li | P4 | BB |
| Tetrathiomolybdate | National Center for Research Resources (NCRR) | P3 | B |
| Bis-Choline Tetrathiomolybdate | Alexion Pharmaceuticals, Inc. | P2 | B |
+11 more in the Wilson Disease cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Alxn1840 in Wilson Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/alxn1840-wilson-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →